scispace - formally typeset
Y

Yifeng Xia

Researcher at Salk Institute for Biological Studies

Publications -  25
Citations -  2152

Yifeng Xia is an academic researcher from Salk Institute for Biological Studies. The author has contributed to research in topics: Cancer & NFKB1. The author has an hindex of 15, co-authored 22 publications receiving 1737 citations. Previous affiliations of Yifeng Xia include Chinese Academy of Sciences & Fudan University.

Papers
More filters
Journal ArticleDOI

NF-κB, an Active Player in Human Cancers

TL;DR: Because of its vital role in various biologic activities, components of the NF-κB pathway need to be carefully selected and evaluated to design targeted therapies.
Journal ArticleDOI

Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50.

TL;DR: A unique pharmacological mechanism of Andro’s protective anti-inflammatory actions is revealed, which suppressed the activation of NF-κB in stimulated endothelial cells and abrogated the cytokine- and endotoxin-induced peritoneal deposition of neutrophils, attenuated septic shock, and prevented allergic lung inflammation in vivo.
Journal ArticleDOI

IKK biology: IKK biology

TL;DR: This review highlights some of the major advances in the studies of the process of IKK activation and the biological roles of I Kurdistan kinase family members, with a focus on NF‐κB‐independent functions.
Journal ArticleDOI

Phosphorylation of p53 by IκB kinase 2 promotes its degradation by β-TrCP

TL;DR: This study shows that IκB kinase 2 (IKK2/IKKβ), which is critical for NF-κB activation, also phosphorylates p53, and suggests that blocking of IKK2 and β-TrCP1 could be a means of regulating p53 stability and thereby modulating its biological activity.
Journal ArticleDOI

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model

TL;DR: A lentiviral-vector-mediated mouse model enables generation of non-small-cell lung cancer from less than 100 alveolar epithelial cells, and the role of IKK2 and NF-κB in lung-cancer development is investigated, suggesting the possible application of Ikk2 and Timp-1 inhibitors in treating lung cancer.